Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

OASIS: Open-label, Dose-escalation, Phase 1/2a Study of the Safety and Tolerability of Suprachoroidally Administered CLS-AX Following Intravitreal Anti-VEGF Therapy in Subjects With Neovascular Age-related Macular Degeneration

NCT04626128 is registered in ClinicalTrials.gov with Clearside Biomedical, Inc. as lead sponsor.

NCT NCT04626128
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04626128 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
OASIS: Open-label, Dose-escalation, Phase 1/2a Study of the Safety and Tolerability of Suprachoroidally Administered CLS-AX Following Intravitreal Anti-VEGF Therapy in Subjects With Neovascular Age-related Macular Degeneration
Lead sponsor
Clearside Biomedical, Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
December 15, 2020
Completion date
October 13, 2022
Enrollment
27 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

neovascular age-related macular degeneration